TSH RECEPTOR MULTIMERIZATION

TSH 受体多聚化

基本信息

项目摘要

DESCRIPTION (provided by applicant): The thyrotropin receptor (TSHR), expressed on the plasma membrane of thyroid epithelial cells as well as a variety of extra-thyroidal sites, is central to the regulation of thyroid growth and function. The TSHR is also the major autoantigen in the autoimmune hyperthyroidism known as Graves' disease where T cells and autoantibodies are directed at the TSHR. Our laboratory first demonstrated the existence of multimeric TSHR forms in native thyroid tissue and more recently we modeled such forms in transfected cells by using functionally tagged TSHRs and fluorescence resonance energy transfer (FRET). This competitive renewal application continues these studies with four specific aims: Specific AIM 1 - To determine the transmembrane contact sites of TSHR multimers. In previous studies we have determined that Y110 in the TSHR ectodomain is an important contact site for ectodomain dimerization and are currently pursuing complex mutational approaches, based on detailed molecular modeling, to determine the sites within the transmembrane domain which are responsible for the major multimeric forms of the full length TSHR. Specific AIM 2 - To determine the role of TSH ligand in TSH receptor multimerization.. Our preliminary data have suggested that TSH reduces TSHR multimers in FRET and Co-IP experiments but the mechanism for this effect is unclear. We will, therefore, further evaluate the influence of TSH induced regulation of the TSHR using bioinformatic and biochemical approaches. Specific AIM 3 - To illustrate that TSHRs reside within lipid rafts, are TSH ligand regulated, and are primary centers of signal initiation. Our data indicate that TSHR forms can be found in lipid raft compartments. Since lipid rafts are centers for signal transduction, we hypothesize that TSHRs within lipid rafts are major signal initiators and will examine this concept in detail. Specific AIM 4 - To test the hypothesis that TSHRs in lipid rafts are resistant to internalization. Internalization leads to the termination of signal transduction and would normally be expected to control excessive hyperstimulation as seen in Graves' disease. Internalization of TSHRs is regulated by the binding of ¿-arrestin to phosphorylated receptors. Lipid rafts are centers of arrestin binding and in other receptor systems have been found to reduce the speed of receptor internalization. This may prolong receptor signaling which can have profound consequences in thyroid disease. We will therefore perform a detailed analysis including time-lapse imaging, to determine the role of arrestin and the signaling consequences. Significance Of the study: The overall aim of this grant is to understand the structure-function relationship of TSH receptor multimers and their role within and without lipid rafts. Understanding the biology of TSHRs may lead to better strategies to control excessive TSHR activation seen in human disease. Relevance: Thyroid disease is common amongst our VA patients and affects some 10% of the population with increasing prevalence with age. Autoimmune thyroid disease, while most common in women, often affects men to a worse degree. This is particularly true for Graves' eye disease. Hence, studies to investigate the cause of autoimmune thyroid disease are highly relevant to the mission of the VA and in addition serve as a model for all other autoimmune diseases including rheumatoid arthritis, multiple sclerosis and Type 1 Diabetes.
描述(由申请人提供): 甲状腺素受体(TSHR)在甲状腺上皮细胞的质膜上表达,以及多种甲状腺外部位,是调节甲状腺生长和功能的核心。 TSHR也是自身免疫性甲状腺功能亢进症的主要自身抗原,称为Graves疾病,T细胞和自身抗体针对TSHR。我们的实验室首先证明了在天然甲状腺组织中存在多聚体TSHR形式,最近我们通过使用功能标记的TSHR和荧光共振能传递(FRET)对翻译细胞中的这种形式进行了建模。这种竞争性更新应用程序以四个具体的目的继续这些研究: 具体目标1-确定TSHR多聚体的跨膜接触位点。 在先前的研究中,我们已经确定TSHR外生域中的Y110是一个重要的接触位点,用于基于分子建模,目前正在采用复杂的突变方法,以确定跨膜结构域中的位点,这些位点负责全长TSHR的主要多层形式。 具体目的2-确定TSH配体在TSH受体多饮食中的作用。 我们的初步数据表明,TSH可以减少FRET和CO-IP实验中的TSHR多聚体,但这种效果的机制尚不清楚。因此,我们将使用生物学和生化方法进一步评估TSH诱导的TSHR调节的影响。 特定目的3-以说明TSHR居住在脂质筏中,由TSH配体调节,并且 是信号启动的主要中心。 我们的数据表明可以在脂质筏室中找到TSHR形式。由于脂质筏是 信号转导中心,我们假设脂质筏中的TSHR是主要信号启动器,将详细检查该概念。 特定目的4-检验脂质筏中TSHR的假设具有抵抗力。 内部化导致信号转导的终止,通常预计将控制过度过度刺激,如坟墓疾病所见。 TSHR的内在化受� -arrestin与磷酸化受体的结合来调节。脂质筏是抑制蛋白结合的中心,在其他受体系统中,脂质筏可降低受体内在化的速度。这可能会延长受体信号传导,这可能会对甲状腺疾病产生深远的影响。因此,我们将进行详细的分析,包括延时成像,以确定停滞蛋白的作用和信号传导后果。 研究的意义:这笔赠款的总体目的是了解结构功能 TSH受体多聚体的关系及其在脂质筏中的作用。了解TSHR的生物学可能会导致更好地控制人类疾病中过度TSHR激活的策略。 关联: 甲状腺疾病在我们的VA患者中很常见,并且随着年龄的增长而影响大约10%的人口。自身免疫性甲状腺疾病虽然在女性中最常见,但通常会影响男性。对于Graves的眼部疾病尤其如此。因此,研究 调查自身免疫性甲状腺疾病的原因与VA的任务高度相关 添加是所有其他自身免疫性疾病,包括类风湿关节炎,多发性硬化症和1型糖尿病的模型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TERRY Francis DAVIES其他文献

TERRY Francis DAVIES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TERRY Francis DAVIES', 18)}}的其他基金

Thyrotropin Receptor, Thyrotropin and Mechanisms of Bone Loss
促甲状腺素受体、促甲状腺素与骨丢失机制
  • 批准号:
    10182095
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Thyrotropin Receptor, Thyrotropin and Mechanisms of Bone Loss
促甲状腺素受体、促甲状腺素与骨丢失机制
  • 批准号:
    9317142
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Thyrotropin Receptor, Thyrotropin and Mechanisms of Bone Loss
促甲状腺素受体、促甲状腺素与骨丢失机制
  • 批准号:
    9906208
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
TSH RECEPTOR AUTOREGULATION
TSH 受体自动调节
  • 批准号:
    9887511
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
TSH RECEPTOR AUTOREGULATION
TSH 受体自动调节
  • 批准号:
    10456019
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
TSH RECEPTOR MULTIMERIZATION
TSH 受体多聚化
  • 批准号:
    8597377
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
TSH RECEPTOR AUTOREGULATION
TSH 受体自动调节
  • 批准号:
    9037499
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
TSH RECEPTOR MULTIMERIZATION
TSH 受体多聚化
  • 批准号:
    8397573
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
TSH RECEPTOR AUTOREGULATION
TSH 受体自动调节
  • 批准号:
    9280772
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
TSH RECEPTOR MULTIMERIZATION
TSH 受体多聚化
  • 批准号:
    8245568
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Mechanism and Function of the Supercomplex KARATE in Insulin Signaling
超级复合物空手道在胰岛素信号传导中的机制和功能
  • 批准号:
    10444290
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers
开发治疗鳞状头颈癌的新型治疗分子
  • 批准号:
    10666868
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
PI3 Kinase Inactivation in Myelodysplastic Syndrome
骨髓增生异常综合征中的 PI3 激酶失活
  • 批准号:
    10518821
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
PI3 Kinase Inactivation in Myelodysplastic Syndrome
骨髓增生异常综合征中的 PI3 激酶失活
  • 批准号:
    10476196
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
AKT as a resistance mechanism to cell cycle and endocrine therapies in ER+ breast cancer
AKT 作为 ER 乳腺癌细胞周期和内分泌治疗的耐药机制
  • 批准号:
    10599693
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了